Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
The impact of S6K1 kinase on neuroblastoma cell proliferation is independent of GLI1 signaling.
[esophageal adenocarcinoma]
The
crosstalk
between
Hedgehog
(
HH
)
signaling
and
other
signal
transduction
cascades
has
been
extensively
studied
in
different
cancers
.
In
neuroblastoma
,
mTOR
/
S
6
K
1
signaling
is
known
to
have
a
role
in
the
development
of
this
disease
and
recent
evidence
also
implicates
the
HH
pathway
.
Moreover
,
S
6
K
1
kinase
has
been
shown
to
phosphorylate
GLI
1
,
the
effector
of
HH
signaling
,
promoting
GLI
1
transcriptional
activity
and
oncogenic
function
in
esophageal
adenocarcinoma
.
In
this
study
,
we
examined
the
possible
interplay
of
S
6
K
1
and
GLI
1
signaling
in
neuroblastoma
.
siRNA
knockdowns
were
used
to
suppress
S
6
K
1
and
GLI
1
expression
,
and
the
siRNA
effects
were
validated
by
real-time
PCR
and
Western
blotting
.
Cell
proliferation
analysis
was
performed
with
the
EdU
incorporation
assay
.
Cytotoxic
analysis
with
increasing
concentrations
of
PI
3
K
/
mTOR
and
GLI
inhibitors
,
individually
and
in
combination
,
was
used
to
determine
drug
response
.
Although
knockdown
of
either
S
6
K
1
or
GLI
1
reduces
the
cellular
proliferation
of
neuroblastoma
cells
,
there
is
little
effect
of
S
6
K
1
on
the
expression
of
GLI
1
mRNA
and
protein
and
on
the
capacity
of
GLI
1
to
activate
target
genes
.
No
detectable
phosphorylation
of
GLI
1
is
observed
prior
or
following
S
6
K
1
knockdown
.
GLI
1
overexpression
can
not
rescue
the
reduced
proliferation
elicited
by
S
6
K
1
knockdown
.
Moreover
,
inhibitors
of
PI
3
K
/
mTOR
and
GLI
signaling
reduced
neuroblastoma
cell
growth
,
but
no
additional
growth
inhibitory
effects
were
detected
when
the
two
classes
of
drugs
were
combined
.
Our
results
demonstrate
that
the
impact
of
S
6
K
1
kinase
on
neuroblastoma
cells
is
not
mediated
through
modulation
of
GLI
1
expression
/
activity
.
Diseases
Validation
Diseases presenting
"but no additional growth inhibitory effects were detected when the two classes of drugs were combined"
symptom
esophageal adenocarcinoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom